Anti-CD99 CAR T-cell therapy (Wuhan Bio-Raid)

靶向CD99嵌合抗原受体T细胞疗法（武汉波睿达生物）

Report date: 2024/12/03 20:00:08

Base Information

Drug NameAnti-CD99 CAR T-cell therapy (Wuhan Bio-Raid)
Drug Alias NameAnti-CD99 chimeric antigen receptor T-cell therapy -(Wuhan Bio Raid Biotechnology)靶向CD99嵌合抗原受体基因修饰的自体T细胞疗法（武汉波睿达生物）BRD-03
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD99 antigen modulators
TargetsCD99 antigen
Therapy Area/IndicationsSarcomaOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWuhan BioRaid Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan BioRaid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSarcomaOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A